An Investigation Into The Policies And Provision Of Seclusion In Three Health Care Settings In South Australia
Funder
National Health and Medical Research Council
Funding Amount
$61,088.00
Summary
The study will investigate the policies and practices of seclusion in both traditional nursing and corrections health clinical settings in South Australia; a much under-researched but, nevertheless, important and contentious area. It will compare and contrast the formal policies and guidelines pertaining to seclusion and its place within the therapeutic philosophy of the facility. It will also consider the de facto practices, the physical provisions for seclusion areas and their relationship to ....The study will investigate the policies and practices of seclusion in both traditional nursing and corrections health clinical settings in South Australia; a much under-researched but, nevertheless, important and contentious area. It will compare and contrast the formal policies and guidelines pertaining to seclusion and its place within the therapeutic philosophy of the facility. It will also consider the de facto practices, the physical provisions for seclusion areas and their relationship to the wider ward environment, the ward audit and records of the use of seclusion and related practice. Furthermore, through interviews with direct care staff, it will examine personal and professional reflections on these issues and begin to develop recommendations for best practice. Therefore, by virtue of its clinical and service focus in Nursing and allied health areas, it falls within the criteria for Special Initiative Funding.Read moreRead less
Pathophysiology And Alternative Preventative Strategy For Breast Cancer Chemotherapy-induced Bone Loss
Funder
National Health and Medical Research Council
Funding Amount
$540,356.00
Summary
Combination cytotoxic chemotherapy is the current optimal approach for treating breast cancer in premenopausal women. However, long-term skeletal defects (osteoporosis and fractures) caused by the chemotherapy have become an increasingly serious problem due to its intensified use and improved patient survival rate. This project seeks to elucidate the mechanisms for chemotherapy-induced bone defects and to initiate development of a preventative treatment using natural bioactive micronutrients.
Role Of Immediate Early Gene Induction And AP-1 Activation In HDAC Inhibitor Induced Apoptosis.
Funder
National Health and Medical Research Council
Funding Amount
$524,820.00
Summary
Histone deacetylase inhibitors (HDACi) are a novel class of anti-tumor agents, recently approved for the treatment of cutaneous T-cell lymphoma. The goal of this study is to improve our understanding of how this class of drug induces tumor cell death. These studies are designed to provide insight into which patients are most likely to benefit from treatment with these agents. Second, they will provide direction into how the therapeutic efficacy of HDACi may be enhanced, through combination with ....Histone deacetylase inhibitors (HDACi) are a novel class of anti-tumor agents, recently approved for the treatment of cutaneous T-cell lymphoma. The goal of this study is to improve our understanding of how this class of drug induces tumor cell death. These studies are designed to provide insight into which patients are most likely to benefit from treatment with these agents. Second, they will provide direction into how the therapeutic efficacy of HDACi may be enhanced, through combination with other existing therapeutics.Read moreRead less
Improving Treatment Outcome In Paediatric Acute Lymphoblastic Leukaemia By Minimal Residual Disease Detection And Pharmacokinetics
Funder
National Health and Medical Research Council
Funding Amount
$609,759.00
Summary
The main objective of this project is to make substantial improvements in the treatment of patients with childhood leukaemia by greater use of molecular diagnostics to measure minimal residual disease (MRD) and pharmacokinetic testing to determine the effectiveness of a key chemotherapy drug (PEG-L-Asparaginase) in Australian patients enrolled on an international clinical trial which has been designed to reduce the incidence of both relapses and long term side-effects.